Recent Investment Analysts’ Ratings Updates for Inspire Medical Systems (INSP)

Inspire Medical Systems (NYSE: INSP) has recently received a number of price target changes and ratings updates:

• 11/5/2024 – Inspire Medical Systems had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $260.00 price target on the stock, up previously from $255.00.
• 11/5/2024 – Inspire Medical Systems had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $260.00 price target on the stock.
• 11/5/2024 – Inspire Medical Systems had its price target raised by analysts at Robert W. Baird from $240.00 to $252.00. They now have an “outperform” rating on the stock.
• 11/5/2024 – Inspire Medical Systems had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $200.00 price target on the stock, up previously from $170.00.
• 11/5/2024 – Inspire Medical Systems had its price target raised by analysts at Wells Fargo & Company from $187.00 to $198.00. They now have an “equal weight” rating on the stock.
• 9/30/2024 – Inspire Medical Systems had its “buy” rating reaffirmed by analysts at Truist Financial Co.. They now have a $240.00 price target on the stock, up previously from $217.00.
• 9/10/2024 – Inspire Medical Systems had its price target raised by analysts at Leerink Partners from $167.00 to $197.00. They now have a “market perform” rating on the stock.

Inspire Medical Systems Trading Down 5.3 %

INSP stock opened at $200.47 on Friday. The stock has a market capitalization of $5.98 billion, a P/E ratio of 187.36 and a beta of 1.36. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $257.40. The firm has a 50-day moving average price of $201.94 and a 200-day moving average price of $179.94.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.54. The company had revenue of $203.20 million during the quarter, compared to the consensus estimate of $197.59 million. Inspire Medical Systems had a return on equity of 5.51% and a net margin of 4.37%. The firm’s revenue was up 32.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. As a group, equities analysts predict that Inspire Medical Systems, Inc. will post 0.75 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Shawn Mccormick sold 800 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $220.00, for a total value of $176,000.00. Following the transaction, the director now directly owns 23,140 shares in the company, valued at $5,090,800. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Shawn Mccormick sold 800 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $220.00, for a total value of $176,000.00. Following the transaction, the director now directly owns 23,140 shares in the company, valued at $5,090,800. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Randy Ban sold 4,861 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $188.55, for a total value of $916,541.55. Following the transaction, the insider now owns 3,056 shares in the company, valued at approximately $576,208.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,692 shares of company stock worth $1,099,207. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Inspire Medical Systems

Several hedge funds have recently modified their holdings of INSP. Russell Investments Group Ltd. raised its holdings in shares of Inspire Medical Systems by 98.9% in the 1st quarter. Russell Investments Group Ltd. now owns 31,933 shares of the company’s stock worth $6,859,000 after purchasing an additional 15,877 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Inspire Medical Systems by 51.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 459,766 shares of the company’s stock worth $98,754,000 after purchasing an additional 156,893 shares during the last quarter. Tidal Investments LLC bought a new position in shares of Inspire Medical Systems during the first quarter valued at about $1,151,000. AQR Capital Management LLC increased its position in shares of Inspire Medical Systems by 152.7% during the second quarter. AQR Capital Management LLC now owns 231,845 shares of the company’s stock valued at $31,028,000 after buying an additional 140,090 shares during the period. Finally, Teachers Retirement System of The State of Kentucky grew its holdings in Inspire Medical Systems by 27.1% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 40,501 shares of the company’s stock worth $8,699,000 after purchasing an additional 8,625 shares during the period. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.